Medicare GLP-1 Bridge Program Launches at 11% Record Adult Usage, Expanding Access for Millions

The Gallup National Health and Well-Being Index documented nearly fourfold growth from 3% in 2024, with 15% lifetime use. The CMS Bridge pilot operates outside standard Part D rules through 2027, covering Foundayo, Wegovy, and Zepbound KwikPen for adults 18+ meeting BMI thresholds or linked conditions like hypertension or prior cardiovascular events. This addresses the longstanding statutory exclusion of weight-loss indications from Part D while diabetes or sleep apnea coverage continues separately.

Program design creates direct cost and access shifts: the fixed $50 monthly copay does not apply to deductibles or out-of-pocket maxima and excludes Extra Help subsidies. National obesity prevalence fell from 39.9% in 2022 to 36.4% in 2026 per the same Gallup data, though diabetes incidence remained flat. Observational trends cannot isolate GLP-1 effects from concurrent lifestyle or diagnostic changes.

Original reporting understates equity risks and adherence questions. Lower-income and rural enrollees face higher effective barriers because the copay sits outside plan protections, while real-world discontinuation rates in observational cohorts often exceed 50% within 12 months. No randomized data yet track cardiovascular or mortality outcomes specifically under the Bridge eligibility criteria.

Next steps require CMS to report Bridge enrollment and discontinuation by mid-2027 alongside linked claims data on hospitalizations and glycemic control. Sustained population-level obesity declines below 35% would need confirmation in longitudinal surveys controlling for selection bias.